The stem cell factor antibody enhances the chemotherapeutic effect of adriamycin on chemoresistant breast cancer cells

Cancer Cell International

Volumn 12, Issue , 2012, Pages

  Jelly, Neil D ^a   Hussain, Issam I ^a   Eremin, Jennifer ^b   Eremin, Oleg ^b,c   El Sheemy, Mohamed ^a,b  

^a UNIVERSITY OF LINCOLN   (United Kingdom)

^b LINCOLN COUNTY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD24 ANTIGEN; CYTOKINE ANTIBODY; DOXORUBICIN; LIPOCORTIN 5; PROTEIN BCL 2; STEM CELL FACTOR ANTIBODY; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL CULTURE; CANCER RESISTANCE; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION;

EID: 84861473676     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-12-21     Document Type: Article

References (30)

1. Washbrook E. Risk factors and epidemiology of breast cancer. Wom Health Med 2006, 3:8-14.
2. Atalay C, Gurhan ID, Irkkan C, Gundaz U. Multidrug Resistance in Locally Advanced Breast Cancer. Tumour Biol 2006, 27:309-318. 10.1159/000096086, 17033200.
3. Chuthapisith S, Layfield R, Kerr ID, Hughes C, Eremin O. Proteomic profiling of MCF-7 breast cancer cells with chemoresistance to different types of anti-cancer drugs. Int J Oncol 2006, 30:1545-1551.
4. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, Margolese R, Theoret H, Soran A, Wickerham DL, Wolmark N. National Surgical Adjuvant Breast and Bowel Project Protocol B-27: The effect on tumour response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003, 21:4165-4174. 10.1200/JCO.2003.12.005, 14559892.
5. Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, Ah-See AK, Eremin O, Walker LG, Sarkar TK, Eggleton SP, Ogston KN. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002, 20:1456-1466. 10.1200/JCO.20.6.1456, 11896092.
6. Chollet P, Charrier S, Brain E, Curé H, van Praagh I, Feillel V, de Latour M, Dauplat J, Misset JL, Ferrière JP. Clinical and pathological response to primary chemotherapy in operable breast cancer. Eur J Cancer 1997, 33:62-866.
7. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz AB, Hoehn JL, Lees AW, Dimitrov NV, Bear HD. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1998, 15:2483-2493.
8. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002, 53:615-627. 10.1146/annurev.med.53.082901.103929, 11818492.
9. Chuthapisith S, Eremin J, El-Sheemy M, Eremin O. Breast cancer chemoresistance: Emerging importance of cancer stem cells. Surg Oncol 2009, 20:1-6.
10. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100:57-70. 10.1016/S0092-8674(00)81683-9, 10647931.
11. Lu C, Hassan HT. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cell. Leuk Res 2006, 30:296-302. 10.1016/j.leukres.2005.06.026, 16112192.
12. Workman P. Challenges of PK/PD measurements in modern drug development. Eur J Cancer 2002, 38:2189-2193. 10.1016/S0959-8049(02)00395-7, 12387843.
13. Diéras V, Fumoleau P, Romieu G, Tubiana-Hulin M, Namer M, Mauriac L, Guastalla JP, Pujade-Lauraine E, Kerbrat P, Maillart P, Pénault-Llorca F, Buyse M, Pouillart P. Randomized Parallel Study of Doxorubicin Plus Paclitaxel and Doxorubicin Plus Cyclophosphamide as Neoadjuvant Treatment of Patients with Breast Cancer. J Clin Oncol 2004, 22:4958-4965. 10.1200/JCO.2004.02.122, 15611510.
14. Zhang J, Lahti JM, Bruce A, He L, Parihar K, Fan C, Grenet J, Liu L, Kidd VJ, Cormier S, Tang D. Identification of an ataxia telangiectasia-mutated protein mediated surveillance system to regulate Bcl-2 overexpression. Oncogene 2006, 25:5601-5611. 10.1038/sj.onc.1209565, 16636671.
15. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005, 5:275-284. 10.1038/nrc1590, 15803154.
16. Martin SJ, Reutelingsperger CP, McGahon AJ, Rader JA, van Schie RC, LaFace DM, Green DR. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis. J Exp Med 1995, 182:1545-1556. 10.1084/jem.182.5.1545, 2192182, 7595224.
17. Glaspy JA, Shpall EJ, LeMaistre CF, Briddell RA, Menchaca DM, Turner SA, Lill M, Chap L, Jones R, Wiers MD, Sheridan WP, McNiece IK. Peripheral Blood Progenitor Cell Mobilization Using Stem Cell Factor in Combination With Filgrastim in Breast Cancer Patients. Blood 1997, 90:2939-2951.
18. Facon T, Harousseau JL, Maloisel F, Attal M, Odriozola J, Alegre A, Schroyens W, Hulin C, Schots R, Marin P, Guilhot F, Granena A, De Waele M, Pigneux A, Méresse V, Clark P, Reiffers J. Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized, controlled trial. Blood 1999, 94:1218-1225.
19. Welke P, Schadendorf D, Artuc M, Grabbe J, Henz BM. Expression of SCF splice variants in human melanocytes and melanoma cell lines: potential prognostic implications. Br J Cancer 2000, 82:1453-1458. 10.1054/bjoc.1999.1076, 2363371, 10780526.
20. Yasuda A, Sawai H, Takahashi H, Ochi N, Matsuo Y, Funahashi H. The stem cell factor/c-kit receptor pathway enhances proliferation and invasion of pancreatic cancer cells. Mol Canc 2006, 5:46.
21. Sun L, Hui AM, Su Q, Vortmeyer A, Kotliarov Y, Pastorino S. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Canc Cell 2006, 4:287-300.
22. Hirano K, Shishido-Hara Y, Kitazawa A, Kojima K, Sumiish A, Umino M. Expression of stem cell factor (SCF), a KIT ligand, in gastrointestinal stromal tumours (Gist's): A potential marker for tumour proliferation. Pathol Res Pract 2008, 204:799-807. 10.1016/j.prp.2008.05.002, 18602222.
23. Attoub S, Rivat C, Rodrigues S, Van Bocxlaer S, Bedin M, Bruyneel E. The c-kit Tyrosine Kinase Inhibitor STI571 for Colorectal Cancer Therapy. Cancer Res 2002, 62:4879-4883.
24. Ulivi P, Zoli W, Medri L, Amadori D, Saragoni L, Barbanti F, Calistri D, Silvestrini R. c-kit and SCF expression in normal and tumor breast tissue. Breast Canc Res Treat 2004, 83:33-42.
25. Zhang W, Stoica G, Tasca SI, Kelly KA, Meininger CJ. Modulation of Tumor Angiogenesis by Stem Cell Factor. Cancer Res 2000, 60:6757.
26. Rappa G, Anzanello F, Lorico A. CD24 expression and breast cancer Stem cell phenotype. J Clin Oncol 2009, 27:15. s.
27. Gao Q, Choi Y-P, Kang S, Youn JH, Cho N-H. CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene 2010, 29:2672-2680. 10.1038/onc.2010.35, 20190812.
28. Vairo G, Innesm KM, Adams JM. Bcl-2 has a cell cycle inhibitory function separable from its enhancement of cell survival. Oncogene 1996, 13:1159-1511.
29. Del Bufalo D, Biroccio A, Trisciuoglio D, Bruno T, Floridi A, Aquino A, Zupi G. Bcl-2 has differing effects on the sensitivity of breast cancer cells depending on the antineoplastic drug used. Euro J Canc 2002, 38:2455-2462.
30. Hassan HT. c-Kit expression in human normal and malignant stem cells prognostic and therapeutic implications. Leuk Res 2009, 33:5-10. 10.1016/j.leukres.2008.06.011, 18639336.